SEC 13F Intelligence

Foresite Capital Management IV, LLC / NRIX

Foresite Capital Management IV, LLC’s Nurix Therapeutics Inc Position

Does Foresite Capital Management IV, LLC own Nurix Therapeutics Inc (NRIX)? Not currently — the last reported position was 677.1K shares worth $9M in Q2 2022; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$9M
Q2 2022
Shares
677.1K
% of Portfolio
+2.31%
Quarters Held
8
position exited

Position History NRIX

Reported value by quarter
Q3 ’20: $82MQ3 ’20Q4 ’20: $77MQ4 ’20Q1 ’21: $39MQ1 ’21Q2 ’21: $32MQ2 ’21Q3 ’21: $36MQ3 ’21Q4 ’21: $35MQ4 ’21Q1 ’22: $14MQ1 ’22Q2 ’22: $9MQ2 ’22filingsflow.com
QuarterSharesValue% of Portfolio
Q2 2022677.1K$9M+2.31%
Q1 20221.03M$14M+4.04%
Q4 20211.21M$35M+7.18%
Q3 20211.21M$36M+5.32%
Q2 20211.21M$32M+4.32%
Q1 20211.24M$39M+4.61%
Q4 20202.35M$77M+8.39%
Q3 20202.35M$82M+18.48%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Foresite Capital Management IV, LLC’s full portfolio or all institutional holders of NRIX.